The tone at BDMS’ 2Q25 analyst meeting was neutral. Management revised down its 2025 revenue growth target further to 3-5% yoy to reflect the current ongoing conflict between Thailand and Cambodia. The outlook in 3Q25 is quite challenging as Jul 25 was not a good month for BDMS. Last year’s earnings base was high from the epidemic, and the conflict has yet to die down. However, we still prefer BDMS as a long-term pick. Maintain BUY. Target price: Bt32.00.
KEY HIGHLIGHTS Results COM7 (COM7 TB/BUY/Bt24.50/Target: Bt29.50) 2Q25: Better-than-expected earnings. Electricity Generating (EGCO TB/BUY/Bt113.00/Target: Bt125.00) 2Q25: Results beat expectations, with yield remaining impressive. GFPT (GFPT TB/BUY/Bt10.10/Target: Bt15.50) 2Q25: Earnings beat expectations on solid profitability. Hana Microelectronics (HANA TB/HOLD/Bt22.60/Target: Bt20.00) ...
GREATER CHINA Sector Automobile Weekly: Yoy growth of China’s PEV sales turns negative; lithium price recovers. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Results Geely Auto (175 HK/BUY/HK$18.95/Target: HK$42.00) 2Q25: Core earnings surge 93% yoy, in line; raise target price to HK$42.00. Maintain BUY. Hysan Development (14 HK/BUY/HK$15.67/Target: HK$17.84) ...
BDMS reported a net profit of Bt3.5b in 2Q25 (+4.6% yoy, -19.7% qoq) which is in line with our forecast and the consensus. The top-line came in at Bt26.7b (+4.0% yoy, -4.8% qoq), with main contributions from a mild revenue growth from Thai patients of 3% yoy and strong revenue growth from international patients of 6% yoy. The strong growth from key nations were able to offset a slowdown from the latest Thai-Cambodia conflict. Maintain BUY. Target price: Bt32.00.
GREATER CHINA Economics Money Supply Credit demand remains weak, though money supply improved. Results Nexteer Automotive Group (1316 HK/BUY/HK$6.92/Target: HK$10.00) 1H25: Earnings beat estimates on margins. Upgrade from HOLD to BUY. Raise target price to HK$10.00 Tencent Holdings (700 HK/BUY/HK$586.00/Target: HK$736.00) 2Q25: Resilient results; unfolding AI monetisation in online games...
We expect BDMS to report a net profit of Bt3.4b in 2Q25 (+2.1% yoy). The top-line should be at Bt26.9b (+4.7% yoy, -4.2% qoq), with main contributions from a modest revenue growth from Thai patients and a robust growth from foreign patient arrivals especially due to a strong rebound in Middle East patient arrivals. The latest Thai-Cambodia conflict is causing some slowdown in Cambodian patient arrivals, but we expect it to be only a short-term issue. Maintain BUY. Target price: Bt32.00.
KEY HIGHLIGHTS Results TISCO Financial Group (TISCO TB/HOLD/Bt99.00/Target: Bt96.00) 2Q25: Results in line with consensus; impact from "You Fight We Help" measure should be mostly reflected. Update Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.60/Target: Bt32.00) Expect mild 2Q25 earnings growth. SCGP (SCGP TB/BUY/Bt17.30/Target: Bt21.00) 2Q25 net profit expected to recover qoq, with 2H25 net profit likely to surpass 1H25.
GREATER CHINA Economics Economic Activity Resilient 1H25 growth of 5.3% yoy belies rising downside pressure. Sector Healthcare Weekly: Gaining strength on robust earnings outlook and pipeline growth. Maintain OVERWEIGHT. Property Property sales and prices weakened further in J...
A director at Bangkok Dusit Medical Services Public Company Limited bought 497,000 shares at 20.100THB and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
GREATER CHINA Economics PMI Modest recovery with construction rebound. Sector Macau Gaming Jun 25 GGR beat consensus by 9%; GGR has regained momentum in recent months. INDONESIA Small/Mid Cap Highlights MAP Aktif Adiperkasa (MAPA IJ/NOT RATED/Rp700) Expanding active lifestyle retail business; 1Q25 NPAT up 21% yoy. MAL...
We went to visit BDMS’ hospitals in Phuket and the newly-opened oncology centre. We see a very dominating network expansion by BDMS with a market share of over 85% in Phuket. With the upcoming competition from new hospitals, we believe that BDMS will be able to maintain its strong position given its location advantage and capability in providing up to tertiary care in Phuket. BDMS firmly remains as our top pick in the healthcare sector. Maintain BUY. Target price: Bt32.00.
GREATER CHINA Sector Insurance Weighing the risks and returns. Update Sunny Optical (2382 HK/BUY/HK$65.15/Target: HK$100.00) Takeaways from 2025 Investor Day. Maintain BUY. INDONESIA Strategy Challenging Macro Environment Adds To Case For Rate Cut Our top picks are BBCA, BBRI, ANTM, AMRT, ICBP, CMRY and ERAA. MALAYSIA Sector Automobile ...
The tone at BDMS’ 1Q25 analyst meeting was neutral. Management revised down its 2025 revenue growth target to 4-6% yoy to accommodate Thailand’s weakening GDP. BDMS is now seeking substitute feeder markets for the Middle East, as the high treatment demand from the region is unlikely to be sustainable. We remain optimistic on BDMS, given the decent outlook for 2Q25 and its ability to deliver growth in a challenging economic environment. Maintain BUY. Target price: Bt32.00.
GREATER CHINA Strategy Small-Mid Cap Monthly: 2H25 outlook: Eyeing domestic plays and names with potential turnaround. Sector Automobile: Weekly: Is there an Evergrand in the China auto sector? Maintain MARKET WEIGHT on the sector. Top BUYs: Geely and XPeng. Results CSPC Pharmaceutical Group (1093 HK/HOLD/HK$7.62/Target: HK$7.70): 1Q25: Results miss; expects enhanced pipelines to secure major BD deals. Li Auto Inc (2015 HK/BUY/HK$108.20/Target: HK$145.00): 1Q25: Earnings and forward guidance mi...
BDMS reported a net profit of Bt4.3b in 1Q25 (+6.7% yoy, +0.3% qoq), which is in line with our and consensus estimates. Revenue totalled Bt28.1b (+5.5% yoy, +2.5% qoq), with main contributions from a strong revenue growth of 4% yoy from Thai patients and a robust revenue growth of 11% yoy from international patients. We are impressed with the strong revenue growth from Thai patients which should alleviate doubts on Thai patient sentiment. Maintain BUY. Target price: Bt33.00.
KEY HIGHLIGHTS Results AP Thailand (AP TB/BUY/Bt6.70/Target: Bt9.60) 1Q25: Earnings in line, improvement expected in 2Q25. Bangkok Dusit Medical Services (BDMS TB/BUY/Bt24.10/Target: Bt33.00) 1Q25: Reported earnings in line with decent yoy growth. Berli Jucker (BJC TB/BUY/Bt23.70/Target: Bt28.00) 1Q25: Better-than-expected earnings growth. Electricity Generating PCL (EGCO TB/BUY/Bt109.00/Target: Bt115.00) 1Q25: Solid 1Q25 results with still-impressive yield. Ratch Group...
GREATER CHINA Economics Money Supply: Credit demand weakens in April. Results Tencent Holdings (700 HK/BUY/HK$521.00/Target: HK$650.00): 1Q25: Strong results propelled by robust games and AI-powered ad-tech. INDONESIA Sector Telecommunications: 1Q25: EBITDA stable at -0.8% qoq. Maintain MARKET WEIGHT. MALAYSIA Results Sunway REIT (SREIT MK/BUY/RM1.93/Target: RM2.05): 1Q25: Results in line. Looking ahead, the full reopening of Sunway Carnival Mall Phase 2 and AEON Seri Manjung acquisition are e...
GREATER CHINA Strategy Alpha Picks: May Conviction Calls Add Alibaba, Innovent, Shuanghuan, Trip.com to our BUY list. Take profit on JBM Healthcare and CR Land. Sector Aviation Airlines: 1Q25 results below expectations. Weak fuel prices to support full-year performance. Maintain UNDERWEIGHT. INDONESIA Strategy 1Q25 Results Recap ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.